S&P 500   3,169.26 (+1.31%)
DOW   27,437.34 (+1.31%)
QQQ   219.23 (+1.79%)
AAPL   293.29 (+1.81%)
FB   200.15 (+1.72%)
MSFT   171.98 (+2.33%)
GOOGL   1,402.89 (+1.20%)
AMZN   2,000.15 (+1.39%)
CGC   20.19 (+2.91%)
NVDA   271.02 (+3.42%)
BABA   211.12 (+2.68%)
MU   53.93 (+3.49%)
TSLA   791.11 (-1.10%)
AMD   48.80 (+2.59%)
T   37.29 (-0.16%)
ACB   1.53 (+1.33%)
F   7.45 (+2.90%)
NFLX   376.72 (+4.62%)
PRI   123.52 (+1.73%)
BAC   31.48 (+1.29%)
GILD   71.37 (+1.81%)
S&P 500   3,169.26 (+1.31%)
DOW   27,437.34 (+1.31%)
QQQ   219.23 (+1.79%)
AAPL   293.29 (+1.81%)
FB   200.15 (+1.72%)
MSFT   171.98 (+2.33%)
GOOGL   1,402.89 (+1.20%)
AMZN   2,000.15 (+1.39%)
CGC   20.19 (+2.91%)
NVDA   271.02 (+3.42%)
BABA   211.12 (+2.68%)
MU   53.93 (+3.49%)
TSLA   791.11 (-1.10%)
AMD   48.80 (+2.59%)
T   37.29 (-0.16%)
ACB   1.53 (+1.33%)
F   7.45 (+2.90%)
NFLX   376.72 (+4.62%)
PRI   123.52 (+1.73%)
BAC   31.48 (+1.29%)
GILD   71.37 (+1.81%)
S&P 500   3,169.26 (+1.31%)
DOW   27,437.34 (+1.31%)
QQQ   219.23 (+1.79%)
AAPL   293.29 (+1.81%)
FB   200.15 (+1.72%)
MSFT   171.98 (+2.33%)
GOOGL   1,402.89 (+1.20%)
AMZN   2,000.15 (+1.39%)
CGC   20.19 (+2.91%)
NVDA   271.02 (+3.42%)
BABA   211.12 (+2.68%)
MU   53.93 (+3.49%)
TSLA   791.11 (-1.10%)
AMD   48.80 (+2.59%)
T   37.29 (-0.16%)
ACB   1.53 (+1.33%)
F   7.45 (+2.90%)
NFLX   376.72 (+4.62%)
PRI   123.52 (+1.73%)
BAC   31.48 (+1.29%)
GILD   71.37 (+1.81%)
S&P 500   3,169.26 (+1.31%)
DOW   27,437.34 (+1.31%)
QQQ   219.23 (+1.79%)
AAPL   293.29 (+1.81%)
FB   200.15 (+1.72%)
MSFT   171.98 (+2.33%)
GOOGL   1,402.89 (+1.20%)
AMZN   2,000.15 (+1.39%)
CGC   20.19 (+2.91%)
NVDA   271.02 (+3.42%)
BABA   211.12 (+2.68%)
MU   53.93 (+3.49%)
TSLA   791.11 (-1.10%)
AMD   48.80 (+2.59%)
T   37.29 (-0.16%)
ACB   1.53 (+1.33%)
F   7.45 (+2.90%)
NFLX   376.72 (+4.62%)
PRI   123.52 (+1.73%)
BAC   31.48 (+1.29%)
GILD   71.37 (+1.81%)
Log in

NASDAQ:TTOO - T2 Biosystems Stock Price, Forecast & News

$0.70
-0.02 (-2.77 %)
(As of 02/26/2020 10:18 AM ET)
Today's Range
$0.70
Now: $0.70
$0.76
50-Day Range
$0.73
MA: $1.03
$1.20
52-Week Range
$0.52
Now: $0.70
$5.38
Volume165,432 shs
Average Volume966,523 shs
Market Capitalization$32.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.13
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTOO
CUSIPN/A
Phone781-761-4646

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.34 million
Book Value$0.26 per share

Profitability

Net Income$-51,150,000.00
Net Margins-706.01%

Miscellaneous

Employees153
Market Cap$32.82 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.


T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

How were T2 Biosystems' earnings last quarter?

T2 Biosystems Inc (NASDAQ:TTOO) posted its quarterly earnings data on Monday, February, 24th. The medical equipment provider reported ($0.29) EPS for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.02. The medical equipment provider earned $3.10 million during the quarter. T2 Biosystems had a negative net margin of 706.01% and a negative return on equity of 1,263.80%. View T2 Biosystems' Earnings History.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for T2 Biosystems.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems updated its FY 2020 After-Hours earnings guidance on Monday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $14-17 million, compared to the consensus revenue estimate of $17.62 million.

What price target have analysts set for TTOO?

7 analysts have issued 12-month price objectives for T2 Biosystems' shares. Their forecasts range from $0.40 to $10.00. On average, they anticipate T2 Biosystems' share price to reach $5.63 in the next twelve months. This suggests a possible upside of 700.5% from the stock's current price. View Analyst Price Targets for T2 Biosystems.

What is the consensus analysts' recommendation for T2 Biosystems?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for T2 Biosystems.

What are Wall Street analysts saying about T2 Biosystems stock?

Here are some recent quotes from research analysts about T2 Biosystems stock:
  • 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (2/4/2020)
  • 2. HC Wainwright analysts commented, "We do not currently have a price target on TTOO shares. Risks include, but are not limited to: (1) failure of to achieve commercial success due to market size, penetration rate, and/or competition; (2) failure to secure regulatory approval for T2Lyme; and (3) potential dilution risk." (8/7/2019)

Has T2 Biosystems been receiving favorable news coverage?

News stories about TTOO stock have trended positive on Wednesday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. T2 Biosystems earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for T2 Biosystems.

Are investors shorting T2 Biosystems?

T2 Biosystems saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,120,000 shares, an increase of 16.4% from the January 15th total of 3,540,000 shares. Based on an average trading volume of 623,800 shares, the days-to-cover ratio is currently 6.6 days. Currently, 10.5% of the shares of the stock are sold short. View T2 Biosystems' Current Options Chain.

Who are some of T2 Biosystems' key competitors?

What other stocks do shareholders of T2 Biosystems own?

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the folowing people:
  • Mr. John P. McDonough, CEO, Pres & Director (Age 59)
  • Prof. Michael J. Cima, Co-Founder & Director (Age 59)
  • Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 40)
  • Dr. Tyler E. Jacks, Co-Founder (Age 58)
  • Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Gagnon Securities LLC (0.81%), Levin Capital Strategies L.P. (0.29%), Virtu Financial LLC (0.19%), State Street Corp (0.13%), Oxford Asset Management LLP (0.12%) and Tower Research Capital LLC TRC (0.07%). Company insiders that own T2 Biosystems stock include Alec Barclay, David B Elsbree, John Mcdonough, Michael J Cima, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Institutional Ownership Trends for T2 Biosystems.

Which institutional investors are selling T2 Biosystems stock?

TTOO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp and Gagnon Securities LLC. Company insiders that have sold T2 Biosystems company stock in the last year include Alec Barclay, David B Elsbree, John Mcdonough, Michael J Cima and Thomas J Lowery. View Insider Buying and Selling for T2 Biosystems.

Which institutional investors are buying T2 Biosystems stock?

TTOO stock was bought by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., Virtu Financial LLC, Oxford Asset Management LLP and Tower Research Capital LLC TRC . View Insider Buying and Selling for T2 Biosystems.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $0.70.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $32.82 million and generates $8.34 million in revenue each year. The medical equipment provider earns $-51,150,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. T2 Biosystems employs 153 workers across the globe.View Additional Information About T2 Biosystems.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is http://www.t2biosystems.com/.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]


MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  360 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  646
MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: Coverage Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel